



Helius Medical Technologies Announces First Three Subjects Enrolled in Canadian Multiple Sclerosis Feasibility Study

(Newtown PA) - February 19, 2015 - Helius Medical Technologies ("Helius", or the "Company") announced the enrollment of the first three subjects in the Multiple Sclerosis ("MS") feasibility study at the Montreal Neurological Institute and Hospital and Concordia's PERFORM Center. The trial, *"Examining the efficacy of Non-invasive Neuromodulation in reducing symptoms of Multiple Sclerosis"*, is a double-blind, sham-controlled study of the safety and efficacy of Helius' Portable Neuromodulation Stimulator (PoNS™) device, an investigational medical device that is designed to induce neuromodulation by stimulating the cranial nerves found in the tongue. A total of 14 subjects will receive treatment with the non-invasive brain stimulation device and concomitant physiotherapy designed to improve both balance and gait. The primary endpoint, at 14-weeks, is improvement in gait as quantified by the Dynamic Gait Index (DGI), Sensory Organization Test (SOT) and Functional Magnetic Resonance imaging (fMRI). The study is expected to conclude this summer.

"We are very pleased to begin this trial as the design is the basis of the registrational MS study scheduled to initiate later in the year," said Helius' CEO, Philippe Deschamps.

"The Montreal Neurological Institute and Hospital is excited to be leading the effort in this research. We are proud to be at the forefront of testing new technologies for the treatment of neurological symptoms," said Dr. Gabriel Leonard, Principal Investigator for the study. Dr. Yves Lapierre and Dr. Alain Ptito from the Montreal Neurological Institute and Hospital join Dr. Leonard as investigators in the study.

About the PoNS™

The PoNS™ device is an investigational medical device being studied for the treatment of neurological symptoms caused by disease or trauma. The PoNS™ is currently being studied in the United States for the treatment of balance disorder for subjects with mild to moderate Traumatic Brain Injury (mTBI), and in Canada for the treatment of gait and balance disorder for subjects with MS.

The PoNST™ device is believed to be the first non-invasive means for delivering neurostimulation through the tongue. Researchers believe that use of the tongue as a gateway to the brain may be one of the most natural, non-invasive and direct ways to stimulate the brain. The tongue is anatomically unique, being richly innervated by thousands of nerve fibers and interconnected to the brainstem by two major cranial nerves.

Study Participation:

To learn more about this trial or recruitment opportunities please contact:

Marcel Mazaltarim M.Sc. @ mmazal@neuromtl.com or 1-866-331-3431.

About Helius Medical Technologies (HMT)

Helius Medical Technologies is a medical technology company focused on neurological wellness. HMT seeks to use unique and non-invasive platform technologies that amplify the brain's ability to heal itself. HMT intends to file for U.S. Food and Drug Administration clearance for the PoNST™ device. For more information, please visit www.heliusmedical.com.

About the Montreal Neurological Institute

The Montreal Neurological Institute and Hospital – (“The Neuro”) is a world-leading destination for brain research and advanced patient care. Since its founding in 1934 by renowned neurosurgeon Dr. Wilder Penfield, The Neuro has grown to be the largest specialized neuroscience research and clinical centre in Canada, and one of the largest in the world. The seamless integration of research, patient care, and training of the world's top minds make The Neuro uniquely positioned to have a significant impact on the understanding and treatment of nervous system disorders. The Montreal Neurological Institute is a McGill University research and teaching institute. The Montreal Neurological Hospital is part of the Neuroscience Mission of the McGill University Health Centre.

About PERFORM Centre

PERFORM is a research centre, based in the Montreal community, with a distinctly Concordia approach to healthy lifestyle management. It represents a significant and forward-thinking investment by the Quebec and Canadian governments as well as Concordia University in addressing the broader determinants of health.

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

This news release contains forward-looking statements relating to the completion of the listing of the Company's shares on the Canadian Securities Exchange and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

#

Contact:

Corporate Contact:

Phil Deschamps

614-596-2597

pdeschamps@heliusmedical.com

US Investor Relations Contact:

Todd James

646-378-2926

tjames@troutgroup.com

Canadian Investor Relations:

778-588-7144

info@heliusmedical.com

Media Contact:

Becky Kern

914-772-2310

media@heliusmedical.com